x

Posted 12 February, 2024

SYNLOGIC, INC. appointed new CEO

CEO Change detected for ticker Nasdaq:SYBX in a 8-K filed on 12 February, 2024.


  In connection with the reduction in workforce, the Company and Aoife Brennan, M.B. Ch.B., the Company's President and Chief Executive Officer, agreed on February 8, 2024 that Dr. Brennan's employment with the Company will terminate effective as of March 9, 2024.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of SYNLOGIC, INC.
Health Care/Life Sciences • Biotechnology
Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on August 28, 2017, and is headquartered in Cambridge, MA.
Market Cap
$16.8M
View Company Details
SYNLOGIC, INC. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


In connection with the reduction in workforce, the Company and Aoife Brennan, M.B. Ch.B., the Company's President and Chief Executive Officer, agreed on February 8, 2024 that Dr. Brennan's employment with the Company will terminate effective as of March 9, 2024. The Company expects to enter into a consulting arrangement with Dr. Brennan in connection with her separation. 


On February 8, 2024, Dr. Brennan also resigned from the Company's Board of Directors, effective March 9, 2024. Dr. Brennan's resignation was not as a result of any disagreement between Dr. Brennan and the Company on any matter relating to the Company's operations, policies or practices.